Table 2.
Cycle characteristics and pregnancy outcome in the young, aged, and aged/DHEA groups.
| Parameters | Young (n = 32) |
Aged (n = 25) |
Aged/DHEA (n = 20) |
|---|---|---|---|
| Stimulation duration (days) | 10.2 ± 1.1 | 10.7 ± 2.9 | 10.4 ± 1.8 |
| HMG/FSH dose (IU) | 3040.3 ± 660.1 | 2836.3 ± 812.2 | 2982.1 ± 604.1 |
| No. of oocytes retrieved (n) | 8.7 ± 4.1 | 3.2 ± 2.1 * | 5.2 ± 1.4 *# |
| No. of metaphase II oocytes (n) | 6.4 ± 3.2 | 1.8 ± 1.7 * | 2.3 ± 1.5 * |
| Maturation rate (%) | 60.7 ± 22.1 | 48.1 ± 32.0 * | 62.5 ± 42.1 |
| No. of fertilized oocytes (n) | 8.3 ± 2.4 | 2.5 ± 1.4 * | 2.8 ± 1.9 * |
| Fertilization rate (%) | 71.3 ± 18.6 | 67.8 ± 21.2 | 71.7 ± 22.0 |
| No. of Day 3 embryos (n) | 6.6 ± 3.3 | 1.7 ± 2.1 * | 3.4 ± 1.6 *# |
| No. of top-quality D3 embryos (n) | 3.1 ± 2.1 | 0.7 ± 1.2 * | 2.4 ± 1.7 *# |
| Clinical pregnancy rate % (n) | 53.1% (17/32) | 16.0% (4/25) | 26.3% (6/20) |
| Ongoing pregnancy rate % (n) | 50.0% (16/32) | 16.0% (4/25) | 26.3% (6/20) |
| Live birth rate % (n) | 50.0% (16/32) | 12.0% (3/25) | 16.7% (4/20) |
DHEA, dehydroepiandrosterone; HMG, human menopausal gonadotrophin; FSH, follicle stimulation hormone. * p < 0.05 versus young; # p < 0.05 versus aged.